KLRK1 and acute myeloid leukemia: In NOD/SCID/IL2Rgnull mice, decitabine but not azacitidine was capable of potentiating infused HSPC-NK cells’ antileukemia activity through upregulation of ligands in AML cells (THP-1) for NKG2D and DNAX accessory molecule-1 (DNAM-1) immunoactivating receptors on HSPC-NK cells.